51263 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 15
00:24 UTC
|
DAN
Dana
|
◎ Target | Dan Levy ★★☆☆☆ #2679 | Equal Weight | $33.00→ $35.00+6.1% |
|
Aug 15
00:24 UTC
|
CUZ
Cousins Properties
|
◎ Target | David Rodgers not yet tracked | Outperform | $33.00→ $35.00+6.1% |
|
Aug 15
00:24 UTC
|
CTC.A
Canadian Tire
|
◎ Target | firm only | C$179.00→ C$199.00+11.2% | |
|
Aug 15
00:24 UTC
|
CTC.A
Canadian Tire
|
◎ Target | firm only | Buy | C$115.00→ C$220.00+91.3% |
|
Aug 15
00:24 UTC
|
CTC.A
Canadian Tire
|
◎ Target | firm only | Sec→ r Perform | C$180.00→ C$200.00+11.1% |
|
Aug 15
00:24 UTC
|
CTC.A
Canadian Tire
|
◎ Target | firm only | Sec→ r Perform | C$210.00→ C$209.00-0.5% |
|
Aug 15
00:24 UTC
|
CRWV
CoreWeave
|
◎ Target | Tyler Radke ★★★☆☆ #1227 | Buy | $142.00→ $159.00+12.0% |
|
Aug 15
00:24 UTC
|
CRMD
CorMedix
|
◎ Target | Leonid Timashev ★★★☆☆ #2095 | Outperform | $13.00→ $14.00+7.7% |
|
Aug 15
00:24 UTC
|
CREX
Creative Realities
|
◎ Target | Jon Hickman ★☆☆☆☆ #3145 | Buy | $7.50→ $8.00+6.7% |
|
Aug 15
00:24 UTC
|
CRBU
Caribou Biosciences
|
◎ Target | Alec Stranahan ★★☆☆☆ #2362 | Buy | $6.00→ $5.00-16.7% |
|
Aug 15
00:24 UTC
|
COST
Costain Group
|
◎ Target | firm only | Buy | GBX 240→ GBX 275+14.6% |
|
Aug 15
00:24 UTC
|
CLBT
Cellebrite DI
|
◎ Target | Eric Martinuzzi ★★★★☆ #513 | Buy | $21.00→ $15.00-28.6% |
|
Aug 15
00:24 UTC
|
CLBT
Cellebrite DI
|
◎ Target | Rudy Kessinger ★★★★☆ #814 | Buy | $22.00→ $15.00-31.8% |
|
Aug 15
00:24 UTC
|
CLBT
Cellebrite DI
|
◎ Target | Mike Cikos ★★★★★ #309 | Buy | $15.00→ $12.50-16.7% |
|
Aug 15
00:24 UTC
|
CLBT
Cellebrite DI
|
◎ Target | Brian Essex ★★★☆☆ #1772 | Overweight | $20.00→ $16.00-20.0% |
|
Aug 15
00:24 UTC
|
CHE.UN
Chemtrade Logistics Income Fund
|
◎ Target | firm only | Buy | C$17.25→ C$18.50+7.2% |
|
Aug 15
00:24 UTC
|
CGY
Calian Group
|
◎ Target | firm only | Buy | C$104.00→ C$109.00+4.8% |
|
Aug 15
00:24 UTC
|
CGY
Calian Group
|
◎ Target | firm only | Buy | C$100.00→ C$106.00+6.0% |
|
Aug 15
00:24 UTC
|
CGY
Calian Group
|
◎ Target | firm only | Outperform | C$90.00→ C$105.00+16.7% |
|
Aug 15
00:24 UTC
|
CGY
Calian Group
|
◎ Target | firm only | C$93.00→ C$107.00+15.1% | |
|
Aug 15
00:24 UTC
|
CELC
Celcuity
|
◎ Target | Gil Blum ★★★☆☆ #1823 | Buy | $157.00→ $140.00-10.8% |
|
Aug 15
00:24 UTC
|
CELC
Celcuity
|
◎ Target | Stephen Willey ★★☆☆☆ #2337 | Buy | $175.00→ $150.00-14.3% |
|
Aug 15
00:24 UTC
|
CCOI
Cogent Communications
|
◎ Target | Christopher Schoell not yet tracked | Neutral | $17.00→ $11.00-35.3% |
|
Aug 15
00:24 UTC
|
CCL.B
CCL Industries
|
◎ Target | firm only | Outperform | C$100.00→ C$105.00+5.0% |
|
Aug 15
00:24 UTC
|
CCL.B
CCL Industries
|
◎ Target | firm only | Outperform | C$100.00→ C$107.00+7.0% |
|
Aug 15
00:24 UTC
|
CCL.B
CCL Industries
|
◎ Target | firm only | Outperform | C$104.00→ C$106.00+1.9% |
|
Aug 15
00:24 UTC
|
CCL.B
CCL Industries
|
◎ Target | firm only | Outperform | C$102.00→ C$104.00+2.0% |
|
Aug 15
00:24 UTC
|
CCL.B
CCL Industries
|
◎ Target | firm only | Buy | C$110.00→ C$115.00+4.5% |
|
Aug 15
00:24 UTC
|
CCL.B
CCL Industries
|
◎ Target | firm only | C$104.00→ C$113.00+8.7% | |
|
Aug 15
00:24 UTC
|
CCL.B
CCL Industries
|
◎ Target | firm only | C$103.00→ C$110.00+6.8% | |
|
Aug 15
00:24 UTC
|
CATX
Perspective Therapeutics
|
◎ Target | Alec Stranahan ★★☆☆☆ #2362 | Neutral | $6.00→ $5.00-16.7% |
|
Aug 15
00:24 UTC
|
CAS
Cascades
|
◎ Target | firm only | Sec→ r Outperform | C$16.00→ C$20.50+28.1% |
|
Aug 15
00:24 UTC
|
CARG
CarGurus
|
◎ Target | Ronald Josey ★★★☆☆ #1547 | Neutral | $32.00→ $39.00+21.9% |
|
Aug 15
00:24 UTC
|
CAE
CAE
|
◎ Target | firm only | Buy | C$48.00→ C$49.00+2.1% |
|
Aug 15
00:24 UTC
|
CAE
CAE
|
◎ Target | firm only | Buy | C$43.00→ C$45.00+4.7% |
|
Aug 15
00:24 UTC
|
CADL
Candel Therapeutics
|
◎ Target | Alec Stranahan ★★☆☆☆ #2362 | Neutral | $9.00→ $12.00+33.3% |
|
Aug 15
00:24 UTC
|
CABA
Cabaletta Bio
|
◎ Target | Derek Archila ★★★☆☆ #1904 | Equal Weight | $4.00→ $3.00-25.0% |
|
Aug 15
00:24 UTC
|
BZAI
Blaize
|
◎ Target | Craig Ellis ★★☆☆☆ #2274 | Buy | $4.00→ $2.00-50.0% |
|
Aug 15
00:24 UTC
|
BWXT
BWX Technologies
|
◎ Target | Alexandra Mandery not yet tracked | Hold | $212.00→ $202.00-4.7% |
|
Aug 15
00:24 UTC
|
BURL
Burlington Stores
|
◎ Target | Corey Tarlowe ★★★★☆ #362 | Buy | $365.00→ $410.00+12.3% |
|
Aug 15
00:24 UTC
|
BTGO
BTGO
|
◎ Target | Dan Dolev ★★★☆☆ #1469 | Outperform | $14.00→ $11.00-21.4% |
|
Aug 15
00:24 UTC
|
BTGO
BTGO
|
◎ Target | Peter Christiansen ★★★☆☆ #2145 | Buy | $17.00→ $10.00-41.2% |
|
Aug 15
00:24 UTC
|
BRZE
Braze
|
◎ Target | Nick Altmann ★★★★☆ #434 | Buy | $30.00→ $35.00+16.7% |
|
Aug 15
00:24 UTC
|
BN
Brookfield
|
◎ Target | Mario Saric ★★★★☆ #619 | Sec→ r Outperform | $53.00→ $54.00+1.9% |
|
Aug 15
00:24 UTC
|
BN
Brookfield
|
◎ Target | firm only | Buy | $60.00→ $61.00+1.7% |
|
Aug 15
00:24 UTC
|
BN
Brookfield
|
◎ Target | firm only | Sec→ r Outperform | $53.00→ $54.00+1.9% |
|
Aug 15
00:24 UTC
|
BLTE
Belite Bio
|
◎ Target | Judah Frommer ★★☆☆☆ #2401 | Overweight | $201.00→ $206.00+2.5% |
|
Aug 15
00:24 UTC
|
BLSH
Bullish
|
◎ Target | Chris Brendler ★☆☆☆☆ #2935 | Neutral | $42.50→ $30.00-29.4% |
|
Aug 15
00:24 UTC
|
BLSH
Bullish
|
◎ Target | Kenneth Worthington not yet tracked | Neutral | $26.00→ $25.00-3.8% |
|
Aug 15
00:24 UTC
|
BIRK
Birkenstock
|
◎ Target | Dana Telsey ★★★☆☆ #1537 | Outperform | $45.00→ $50.00+11.1% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.